| Identification | Back Directory | [Name]
E-3810 | [CAS]
1058137-23-7 | [Synonyms]
CS-655
E-3810
AL3810
S 80881
CS-1836
CO-3810
Lucitanib
E-3810 USP/EP/BP
Lucitanib(E3810)
E-3810(Lucitanib)
E 3810; E-3810;CO-3810; S 80881; E-3810
6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-N-methyl-1-naphthamide
6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide
6-[[7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide
1-Naphthalenecarboxamide, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-
6-[[7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide E-3810(Lucitanib) | [Molecular Formula]
C26H25N3O4 | [MDL Number]
MFCD20527751 | [MOL File]
1058137-23-7.mol | [Molecular Weight]
443.49 |
| Chemical Properties | Back Directory | [Boiling point ]
696.5±50.0 °C(Predicted) | [density ]
1.285±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
14.65±0.46(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively[1][2][3]. | [Definition]
ChEBI: A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine. | [in vivo]
Lucitanib (E-3810), at oral dosing of 20 mg/kg for 7 consecutive days, completely inhibits (P<0.01) the bFGF induced angiogenic response compare with the response in vehicle-treated mice. Lucitanib (E-3810) shows a broad spectrum of activity, being active in all the xenografts tested (HT29 colon carcinoma, A2780 ovarian carcinoma, A498, SN12K1, and RXF393 renal carcinomas) with dose-dependent inhibition of tumor growth. E-3810 significantly delays growth during treatment, but tumors resume their growth when treatment is suspended; in a few cases, tumor regression is observed[1]. The activity of Lucitanib (E-3810) given at the doses of 15 mg/kg is tested on MDA-MB-231 breast cancer transplanted subcutaneously, at a late stage, when tumor masses reach 350 to 400 mg. This tumor xenograft is very sensitive to Lucitanib (E-3810), with complete tumor stabilization lasting throughout the 30-day treatment. As in other tumor models, tumors re-grow after withdrawal of Lucitanib (E-3810) at a rate similar to control tumors[3]. | [target]
VEGFR-1 | [IC 50]
VEGFR1: 7 nM (IC50); VEGFR2: 25 nM (IC50); VEGFR3: 10 nM (IC50); FGFR1: 17.5 nM (IC50); FGFR2: 82.5 nM (IC50) | [References]
[1] Bello E, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DOI:10.1158/0008-5472.CAN-10-2700
[2] Colzani M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteomics. 2014 Jun;13(6):1495-509. DOI:10.1074/mcp.M113.034173
[3] Bello E, et al. The tyrosine kinase inhibitor E-3810 combined with NSC 125973 inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther. 2013 Feb;12(2):131-40 DOI:10.1158/1535-7163.MCT-12-0275-T |
|
|